Nitto Denko Group Report 2013

29Nitto Denko Group Report 2013revolutionary treatment for brosis in Japan, the US, China and Australia, and clinical trials are scheduled to start in 2013.Liver cirrhosis, which is one form of organ brosis, is said to be incurable and 6 million people throughout the world are suffering from this intractable disease. This disease is caused by chronic inammation of the liver whereby excess amounts of collagen, which play a role in repairing areas of inammation site, are synthesized from hepatic stellate cells and then deposited. Professor Niitsu thought of a way of delivering drugs directly to the hepatic stellate cells in order to prevent the excessive synthesis of collagen, however there were two issues.The rst was the development of a drug that could suppress the synthesis of collagen. Nucleic acid medicine was used to provide a solution, whereby siRNA was used to suppress a specic RNA function. By suppressing this important factor in the synthesis of collagen it is possible to suppress the synthesis of collagen itself. The second issue was how to deliver it exclusively to the target hepatic stellate cells without degrading the siRNA. Professor Niitsu saw the potential of vitamin A because hepatic stellate cells will specically take up vitamin A.Using this idea coupled with Nitto Denko’s patented drug delivery system (DDS), siRNA (cargo) was inserted into a special carrier (vessel) and vitamin A (navigator) applied to the outside to create a revolutionary new therapeutic agent. Basic patents regarding this new drug were granted rstly in Japan, China and Australia, followed in May 2012 by the US. In March 2013, an Investigational New Drug (IND) application was led with the US Food and Drug Administration to use this therapeutic agent as a treatment for liver cirrhosis and clinical trials will commence during this scal year. Currently there is no drug that will cure liver cirrhosis and if this therapeutic agent can be commercialized it will be the rst of its kind in the world.Nitto Denko is carrying out further research to apply this therapeutic agent not only with regard to liver cirrhosis, but also to other forms of organ brosis to help people suffering from this intractable disease.Nitto Denko Participates in National R&D Project to Develop Flexible OLED Lighting In scal 2012, the Nitto Denko Group participated in the New Energy and Industrial Technology Development Organization’s (NEDO) R&D project regarding the development of a reel-type vacuum deposition method for the efcient production of exible organic light-emitting diode (OLED) lighting. OLED lighting is gaining much attention as the next generation of energy-efcient lighting that will follow the rapidly expanding use of LEDs. It is hoped that the practical application of this process will contribute to the popularization of OLED lighting and the realization of an energy-efcient society, and that the exible nature of the technology will enable the development of unique lighting products that up until now have not been possible.R&D Center Established in Switzerland for Materials related to the Environment and Life SciencesIn July 2012, Nitto Denko established Nitto Denko Europe Technical Centre Sàrl (NET) in the Innovation Square of the École Polytechnique Fédérale de Lausanne (EPFL) in western Switzerland. The new facility, which started R&D operations in October of the same year, is part of the company’s global corporate R&D setup, together with three other facilities in Japan, the US and Asia (Singapore). EPFL is one of the top universities in Europe, with a rich pool of talented personnel from throughout the world, and it is hoped that NET will be able to utilize the university’s network to develop new research themes – especially in environmental and life science-related elds, and conduct collaborative research and development with the university’s researchers in biosciences and chemistry and outside research institution. An overview of the new drug The carrier (vessel) delivers the siRNA drug (cargo) exclusively to the hepatic stellate cells by means of the vitamin A targeting agent (navigator).Drug (Cargo)siRNA suppresses the synthesis of collagen produced by hepatic stellate cells, which is the cause of liver cirrhosis. Carrier (Vessel)Protects the drug in blood circulationTargeting Agent (Navigator)Vitamin A. Navigates the drug and carrier to only the target hepatic stellate cells.CO2 emissionsWater dischargeR&D expensesCapitalinvestmentRecyclingEnergyWaterHumanresourcesProductsNew technologyBusinessactivitySalesOperatingIncomeDividendsSocialcontributionsCorporate governanceRaw materialsManagementSolvent emissionsIndustrial wasteIntellectualproperty